ClinicalTrials.gg
CompletedNCT05593926FLORAUpdated Jan 17, 2024

Fibre suppLements fOR Pre-diAbetes - An Assessment Oral Fibre Supplements on Pre-diabetes Outcome Measures

An interventional study of Myota Metabolic Regulator in Pre-diabetes, sponsored by Myota GmbH. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-01-17.

Sponsored by Myota GmbH · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Glucose Intolerance with a site in United Kingdom — 4 open to participants now, 7 under way, none of them phase 3. Glucose Intolerance · United Kingdom.

Enrollment
10th of 29
61 · median 40
Started
2022
with 2 others
No phase
25 of 38
1 open now
Registered
32nd of 38
by date

Among the 38 studies in Glucose Intolerance with a site in United Kingdom, this one is the 10th largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2022, is one of 25 with no phase, and was the 32nd registered.

Glucose Intolerance

793 studies on the registry are indexed under Glucose Intolerance; 113 are open to participants now.

Browse Glucose Intolerance studies →

Open to participants now

4 of the 38 studies in Glucose Intolerance with a site in United Kingdom are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 68 Glucose Intolerance studies recruiting now, 13 (19%) set no upper age limit and 50 (74%) stop at 75 or younger; 9 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Glucose Intolerance with a site in United Kingdom, or all of them as a file.
02

Study summary

This trial will investigate whether a powdered fibre mix helps maintain healthy blood glucose levels in participants with pre-diabetes, where high blood sugar is a risk of diabetes.

Read the detailed description

Pre-diabetes is characterised by high blood glucose levels, high plasma cholesterol, low-density lipoprotein (LDL) and high-density lipoprotein (HDL). Dietary fibre consumption has been hypothesised to improve these metabolic parameters through the viscous properties, and the production of short-chain fatty acids (SCFA) in the intestine.

03

Conditions studied

  • Pre-diabetes

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able and willing to provide
  • Have a (BMI) of at least 25 kg/m2
  • Men or post menopausal* women aged 18-70
  • Identified as pre-diabetic ( 6.0% (42 mmol/mol) to 6.4% (47 mmol/ mol)) within the previous 12 months
  • Baseline HbA1c result within the range 5.8% (40 mmol/mol) - 6.5% (48 mmol/mol)
  • Willing to complete in clinic blood tests and a participant trial survey
  • Have access to a smartphone or a computer

Exclusion criteria

Exclusion Criteria:

  • Receiving medication to treat Type 1 or Type 2 diabetes in the previous 6 months
  • Have a (BMI) \<25 kg/m2 and >45 kg/m2
  • Loss of more than 5% body weight in last 3 months
  • Current participation in weight loss program or planned in the next 16 weeks
  • use (except for over the counter NSAID's, topical steroids and inhalers)
  • Severe hepatic diseases (including chronic persistent hepatitis, liver cirrhosis or the co-occurrence of positive virus surface antigen and abnormal hepatic transaminase (serum concentrations of or aspartate transaminase >2.5× the upper normal limit))
  • Continuous antibiotic use for >3 days within 4 weeks prior to enrolment
  • Continuous use of weight-loss drug for within 3 months of study entry
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Intervention

    The functional food, Myota Metabolic Regulator, consisting of 20g of a powdered fibre mix, to be taken daily alongside usual diet for 24 weeks.

    Dietary Supplement: Myota Metabolic Regulator

  • No intervention
    Placebo

    Placebo will be 2g of powdered cellulose, to be taken daily alongside usual diet for 24 weeks. Placebo will be 2g of powdered cellulose, to be taken daily alongside usual diet for 24 weeks.

Interventions

  • Dietary supplementMyota Metabolic Regulator

    The functional food, Myota Metabolic Regulator, consisting of 20g of a powdered fibre mix, to be taken daily alongside usual diet for 24 weeks.

06

What researchers measure

Primary outcomes

  1. HbA1c levels

    To compare the effect of Myota's Metabolic Regulator versus placebo on Hemoglobin A1c (HbA1c) levels

    Time frame: 16 weeks

Secondary outcomes

  1. HbA1c levels

    To compare the effect of Myota's Metabolic Regulator versus placebo on Hemoglobin A1c (HbA1c) levels

    Time frame: 24 weeks

  2. Insulin

    To compare the effect of Myota's Metabolic Regulator versus placebo on blood insulin concentration.

    Time frame: 16 and 24 weeks

  3. Insulin sensitivity

    To compare the effect of Myota's Metabolic Regulator versus placebo on insulin sensitivity as measured using ISI-OGTT.

    Time frame: 16 weeks

  4. Lipid profile

    To compare the effect of Myota's Metabolic Regulator versus placebo on cholesterol \[total, low-density lipoprotein (LDL), high-density lipoprotein (HDL)\] and triglycerides levels.

    Time frame: 16 and 24 weeks

  5. Inflammatory markers

    To compare the effect of Myota's Metabolic Regulator versus placebo on inflammatory markers (IL-6, IL-8, IL-10, CRP, TNF-a).

    Time frame: 16 and 24 weeks

  6. Blood pressure

    To compare the effect of Myota's Metabolic Regulator versus placebo on diastolic and systolic blood pressure

    Time frame: 16 and 24 weeks

  7. Overall safety of the Myota Metabolic Regulator

    Number of participants reporting adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Weeks 1-4

  8. To investigate intervention adherence

    A daily intervention adherence questionnaire will be used to assess the extent to which participant's adhered to the intervention. This will consist of two questions: Did you consume the full sachet of study product yesterday? Yes/No \[If no\] Why were you unable to take the product yesterday?

    Time frame: 24 weeks

  9. To investigate usability

    A usability questionnaire will be administered to assess how easily participant's were able to use the intervention or placebo. This will consist of two statements: I found the supplement easy to take. Strongly disagree to Strongly agree (5 options) I would like to take this supplement in my normal daily life. Yes/no

    Time frame: 16 and 24 weeks

07

Study locations

2 sites
  • Albany House Medical Centre
    Wellingborough, Northamptonshire NN8 4RW, United Kingdom
  • Lindus Health
    London, SE1 4GT, United Kingdom
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Aug 2023, 9 months.

Of 32 industry-sponsored interventional studies with no phase under Glucose Intolerance, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 37. This study's 9 months is below that.

Counting every sponsor, half of 285 studies reached it within 26 months; a quarter within 10 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2022
First posted
Oct 26, 2022
StartActual
Nov 16, 2022
Primary completionActual
Aug 26, 2023
CompletionActual
Jan 15, 2024
Last update
Jan 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05593926
Lead sponsor
Myota GmbH
Collaborators
Lindus Health
Responsible party
Dr John Luke Twelves (Medical Director (CRO), Myota GmbH) — Principal investigator
First posted
Oct 26, 2022
Start date
Nov 16, 2022
Primary completion
Aug 26, 2023
Completion
Jan 15, 2024
Last update
Jan 17, 2024

Study contacts

Luke Twelves, Dr
principal investigator · Myota GmbH
Thomas Gurry, PhD
study director · Myota GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion